| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/30/2011 | US20110160300 Renin Inhibitors and Methods of Use Thereof |
| 06/30/2011 | US20110160299 Composition and method |
| 06/30/2011 | US20110160298 Pharmaceutical composition for prevention and/or treatment of bone loss |
| 06/30/2011 | US20110160297 Schweinfurthin analogues |
| 06/30/2011 | US20110160296 Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine |
| 06/30/2011 | US20110160295 Antitumor agent |
| 06/30/2011 | US20110160294 Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| 06/30/2011 | US20110160293 Prmt1 for target genes of cancer therapy and diagnosis |
| 06/30/2011 | US20110160292 Regulation of Integrin Surface Expression |
| 06/30/2011 | US20110160291 Oligonucleotide Compositions and Their Use to Induce Apoptosis |
| 06/30/2011 | US20110160290 Use of extracellular rna to measure disease |
| 06/30/2011 | US20110160289 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 06/30/2011 | US20110160287 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof |
| 06/30/2011 | US20110160286 Allele-specific rna interference |
| 06/30/2011 | US20110160285 Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| 06/30/2011 | US20110160284 Supercoiled minicircle dna for gene therapy applications |
| 06/30/2011 | US20110160283 Modulation of cd40 expression |
| 06/30/2011 | US20110160282 Nucleic-acid pharmaceutical composition for cancer therapy |
| 06/30/2011 | US20110160281 RNA Interference Mediated Inhibition of Vascular Cell Adhesion Molecule (VCAM) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 06/30/2011 | US20110160280 Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
| 06/30/2011 | US20110160279 METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA |
| 06/30/2011 | US20110160278 Methods For Selectively Modulating Survivin Apoptosis Pathways |
| 06/30/2011 | US20110160277 Modulation of 11 beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
| 06/30/2011 | US20110160276 Curcumin derivatives |
| 06/30/2011 | US20110160274 Fenofibrate formulation with enhanced oral bioavailability |
| 06/30/2011 | US20110160273 Co-crystals of duloxetine and cox-inhibitors for the treatment of pain |
| 06/30/2011 | US20110160272 Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy |
| 06/30/2011 | US20110160271 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 06/30/2011 | US20110160270 Deuterium-enriched sdx-101 |
| 06/30/2011 | US20110160268 Compositions and methods for treating lung disorders |
| 06/30/2011 | US20110160267 Method of treating diabetic retinopathy |
| 06/30/2011 | US20110160266 Novel Anti-Arrhythmia Agent |
| 06/30/2011 | US20110160265 Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
| 06/30/2011 | US20110160264 Orally administrable film dosage forms containing ondansetron |
| 06/30/2011 | US20110160263 Small molecule inhibition of PDZ-domain interaction |
| 06/30/2011 | US20110160262 Method of treating retinal vein occlusion |
| 06/30/2011 | US20110160261 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| 06/30/2011 | US20110160260 Method of Treating a Neurodegenerative Disorder |
| 06/30/2011 | US20110160259 Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners |
| 06/30/2011 | US20110160257 Novel salts and polymorphs of desazadesferrothiocin polyether analogues as metal chelation agents |
| 06/30/2011 | US20110160256 Inhibitors of akt activity |
| 06/30/2011 | US20110160255 Inhibitors of akt activity |
| 06/30/2011 | US20110160254 Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria |
| 06/30/2011 | US20110160253 Deuterated tizanidine |
| 06/30/2011 | US20110160252 Pharmaceutical compositions for treatment or prevention of hbv infection |
| 06/30/2011 | US20110160250 Crystalline forms of a factor xa inhibitor |
| 06/30/2011 | US20110160249 5-lipoxygenase-activating protein inhibitor |
| 06/30/2011 | US20110160248 Pyrazole compounds and uses thereof |
| 06/30/2011 | US20110160247 Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression |
| 06/30/2011 | US20110160246 Neurodegenerative Protein Aggregation Inhibition Methods and Compounds |
| 06/30/2011 | US20110160245 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| 06/30/2011 | US20110160244 Phenylpiperidine modulators of mu-opioid receptor |
| 06/30/2011 | US20110160243 Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| 06/30/2011 | US20110160242 Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same |
| 06/30/2011 | US20110160241 New peptidomimetic compounds |
| 06/30/2011 | US20110160240 Polymorphs and salts of a kinase inhibitor |
| 06/30/2011 | US20110160239 Oral administration of peripherally-acting opioid antagonists |
| 06/30/2011 | US20110160238 Octahydroquinolizines for antidiabetic treatment |
| 06/30/2011 | US20110160237 Substituted Heterocyclic Compounds |
| 06/30/2011 | US20110160236 Treating Vascular Events with Statins by Inhibiting PAR-1 and PAR-4 |
| 06/30/2011 | US20110160235 Triazolyl tropane derivatives |
| 06/30/2011 | US20110160234 Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors |
| 06/30/2011 | US20110160233 Anti-viral compounds |
| 06/30/2011 | US20110160232 Certain chemical entities and therapeutic uses thereof |
| 06/30/2011 | US20110160231 Dihydroorotate dehydrogenase as antifungal drug target and quinazolinone-based inhibitors thereof |
| 06/30/2011 | US20110160230 Ceramic matrix for incorporating controlled release drugs, a tablet, method for obtaining the ceramic matrix and method for producing a tablet |
| 06/30/2011 | US20110160229 Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia |
| 06/30/2011 | US20110160228 Dihydro-iso-ca-4 and analogues: potent cytotoxics, inhibitors of tubulin polymerization |
| 06/30/2011 | US20110160227 Prolyl Hydroxylase Inhibitors |
| 06/30/2011 | US20110160226 Substituted Triazolo-Pyrimidine Compounds |
| 06/30/2011 | US20110160225 Compositions and methods of use for treating or preventing lipid related disorders |
| 06/30/2011 | US20110160224 Aripiprazole complex formulation and method |
| 06/30/2011 | US20110160223 NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders |
| 06/30/2011 | US20110160222 Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| 06/30/2011 | US20110160221 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 06/30/2011 | US20110160220 Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| 06/30/2011 | US20110160219 Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient |
| 06/30/2011 | US20110160218 Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles |
| 06/30/2011 | US20110160217 Deuterium enriched analogues of tadalafil as pde5 inhibitors |
| 06/30/2011 | US20110160216 Thymidylate Synthase Haplotype is Associated with Tumor Recurrence in Stage II and Stage III Colon Cancer Patients |
| 06/30/2011 | US20110160215 Substituted Triazolo-Pyrazine Compounds |
| 06/30/2011 | US20110160214 Compositions and methods for eye whitening |
| 06/30/2011 | US20110160213 Pharmaceutical compositions for the treatment of inflammatory and allergic disorders |
| 06/30/2011 | US20110160212 Certain dipeptidyl peptidase inhibitors |
| 06/30/2011 | US20110160211 Cyclopentylacrylamide derivative |
| 06/30/2011 | US20110160210 Control of intraocular pressure using alk5 modulation agents |
| 06/30/2011 | US20110160209 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
| 06/30/2011 | US20110160208 Diaryl-substituted five-membered heterocycle derivative |
| 06/30/2011 | US20110160207 Heterocyclic amide compounds useful as kinase inhibitors |
| 06/30/2011 | US20110160206 Tri-substituted pyrimidine compounds and their use as pde10 inhibitors |
| 06/30/2011 | US20110160205 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| 06/30/2011 | US20110160204 PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS |
| 06/30/2011 | US20110160203 Substituted Pyrrolo-Aminopyrimidine Compounds |
| 06/30/2011 | US20110160202 Pyrazine compounds as phosphodiesterase 10 inhibitors |
| 06/30/2011 | US20110160201 Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it |
| 06/30/2011 | US20110160200 Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
| 06/30/2011 | US20110160199 Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia |
| 06/30/2011 | US20110160198 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
| 06/30/2011 | US20110160197 Substituted Indoles and a Method for the Production and Use Thereof |
| 06/30/2011 | US20110160196 Factor xa inhibitors |